<?xml version='1.0' encoding='utf-8'?>
<document id="27128454"><sentence text="A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients."><entity charOffset="68-84" id="DDI-PubMed.27128454.s1.e0" text="cyclophosphamide" /></sentence><sentence text="Casopitant is a potent and selective neurokinin-1 receptor antagonist formerly under development for a number of indications, including the treatment of chemotherapy-induced nausea and vomiting" /><sentence text=" This study was an open-label, randomized, multi-center, two-period crossover casopitant-cyclophosphamide interaction study"><entity charOffset="89-105" id="DDI-PubMed.27128454.s3.e0" text="cyclophosphamide" /></sentence><sentence text=" Subjects were cancer patients receiving cyclophosphamide based chemotherapy"><entity charOffset="41-57" id="DDI-PubMed.27128454.s4.e0" text="cyclophosphamide" /></sentence><sentence text=" The objectives of the study were to assess the effect of 3-day, repeat-dose, 150 mg oral casopitant on the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (white blood cell count) of single-dose IV cyclophosphamide"><entity charOffset="217-233" id="DDI-PubMed.27128454.s5.e0" text="cyclophosphamide" /></sentence><sentence text=" PK data from 14 evaluable subjects showed the geometric least-squares mean ratios (90% CI) for cyclophosphamide and the metabolite 4-hydroxycyclophosphamide AUC (with:without casopitant) were 1"><entity charOffset="96-112" id="DDI-PubMed.27128454.s6.e0" text="cyclophosphamide" /><entity charOffset="132-157" id="DDI-PubMed.27128454.s6.e1" text="4-hydroxycyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.27128454.s6.e0" e2="DDI-PubMed.27128454.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27128454.s6.e0" e2="DDI-PubMed.27128454.s6.e1" /></sentence><sentence text="03 (0" /><sentence text="975, 1" /><sentence text="09) and 0" /><sentence text="948 (0" /><sentence text="835, 1" /><sentence text="08), respectively" /><sentence text=" Administration of casopitant was well tolerated and did not impact the safety profile of the treatment regimen" /><sentence text=" Casopitant did not affect the expected bone marrow toxicity of cyclophosphamide"><entity charOffset="64-80" id="DDI-PubMed.27128454.s14.e0" text="cyclophosphamide" /></sentence><sentence text=" Co-administration of 150 mg oral casopitant with single-dose IV cyclophosphamide did not appear to result in a clinically relevant change in cyclophosphamide or 4-hydroxycyclophosphamide exposure or safety"><entity charOffset="65-81" id="DDI-PubMed.27128454.s15.e0" text="cyclophosphamide" /><entity charOffset="142-158" id="DDI-PubMed.27128454.s15.e1" text="cyclophosphamide" /><entity charOffset="162-187" id="DDI-PubMed.27128454.s15.e2" text="4-hydroxycyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.27128454.s15.e0" e2="DDI-PubMed.27128454.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27128454.s15.e0" e2="DDI-PubMed.27128454.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27128454.s15.e0" e2="DDI-PubMed.27128454.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27128454.s15.e1" e2="DDI-PubMed.27128454.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27128454.s15.e1" e2="DDI-PubMed.27128454.s15.e2" /></sentence><sentence text=" " /></document>